AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Regenxbio's RGX-121 Review Timeline Extended by FDA
ByAinvest
Monday, Aug 18, 2025 5:48 pm ET1min read
Regenxbio's RGX-121 review by the FDA has been extended. The company develops gene therapy using its proprietary adeno-associated virus platform to address genetic diseases. RGX-121 is being developed to treat Mucopolysaccharidosis type II, a neurodegenerative lysosomal storage disorder.
The U.S. Food and Drug Administration (FDA) has extended the review timeline for Regenxbio's RGX-121, a gene therapy candidate designed to treat Mucopolysaccharidosis type II (MPS II), also known as Hunter syndrome. The Prescription Drug User Fee Act (PDUFA) goal date has been moved from November 9, 2025, to February 8, 2026 [1].Regenxbio announced the extension following the submission of longer-term clinical data for all patients in the pivotal study of RGX-121 (n=13) in response to an FDA information request. These positive 12-month clinical data are consistent with biomarker and neurodevelopmental data previously submitted on the same patients in the BLA [1].
The extension comes after the FDA completed a pre-license inspection and bioresearch monitoring information inspection for the RGX-121 BLA with no observations. No safety-related concerns have been raised by the FDA during the BLA review [1].
Regenxbio's RGX-121 is a one-time AAV therapeutic designed to deliver the iduronate-2-sulfatase (IDS) gene to the central nervous system (CNS), aiming to provide a permanent source of secreted iduronate-2-sulfatase (I2S) protein beyond the blood-brain barrier. This could potentially provide long-term cross correction of cells throughout the CNS, addressing the underlying genetic cause of Hunter syndrome [1].
The company plans to present updated pivotal data during the International Congress of Inborn Errors of Metabolism (ICIEM) in September 2025 [1]. Regenxbio's RGX-121 has received Orphan Drug Product, Rare Pediatric Disease, Fast Track, and Regenerative Medicine Advanced Therapy (RMAT) designations from the FDA [1].
References:
[1] https://finance.yahoo.com/news/regenxbio-announces-fda-review-extension-210000898.html
[2] https://www.prnewswire.com/news-releases/regenxbio-announces-fda-review-extension-of-bla-for-rgx-121-to-treat-patients-with-mps-ii-302532620.html
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet